Theratechnologies Inc. (THTX)

CA — Healthcare Sector
Peers:   OPT  CNTA  NUVL  TARS  GNFT  VRCA  LIAN  IVA  EWTX  VIGL  APLT  LYRA  STTK  VINC  BCAB  PMVP  ELYM  MNOV  PHVS  PEPG 

Automate Your Wheel Strategy on THTX

With Tiblio's Option Bot, you can configure your own wheel strategy including THTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol THTX
  • Rev/Share 1.7961
  • Book/Share -0.4957
  • PB -5.306
  • Debt/Equity -2.0579
  • CurrentRatio 1.0759
  • ROIC 1.2428

 

  • MktCap 120927447.0
  • FreeCF/Share -0.353
  • PFCF -6.9402
  • PE -35.0112
  • Debt/Assets 0.8919
  • DivYield 0
  • ROE 0.1601

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Theratechnologies Reports on its Annual Meeting of Shareholders
THTX
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral

MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.

Read More
image for news Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer
THTX
Published: April 18, 2025 by: Seeking Alpha
Sentiment: Negative

Theratechnologies is likely to accept Future Pak's $255 million offer, presenting a 39%-78% premium over current share prices, despite non-binding risks. The company's HIV franchise, led by EGRIFTA SV, faces competition and supply issues, with uncertain prospects for its new formulation and other niche products. Theratechnologies' financials are dire, with only $4.6 million in cash and a high burn rate, necessitating urgent external financing or a strategic transaction.

Read More
image for news Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer
Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
THTX
Published: April 11, 2025 by: Business Wire
Sentiment: Neutral

WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC (“Future Pak”) today announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnologies Inc. (“Theratechnologies”) (NASDAQ: THTX). The most recent proposal, which remains open for consideration by Theratechnologies and its Board of Directors, offers a cash consideration of $3.51 to $4.50 per share. The proposal represents a total enterprise value of up to $255 million, comprisin.

Read More
image for news Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
THTX
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2024 ended November 30 on Wednesday, February 26, 2025, at 8:30 a.m. ET.

Read More
image for news Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Theratechnologies Resumes Distribution of EGRIFTA SV®
THTX
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced that it has resumed distribution of EGRIFTA SV ® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the Company to release two recently manufactured batches of EGRIFTA SV ® . The product is ready for immediate shipment to network pharmacies.

Read More
image for news Theratechnologies Resumes Distribution of EGRIFTA SV®

About Theratechnologies Inc. (THTX)

  • IPO Date 2009-02-13
  • Website https://www.theratech.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Mr. Paul Lévesque
  • Employees 103

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.